<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04620889</url>
  </required_header>
  <id_info>
    <org_study_id>LFP-15-001</org_study_id>
    <nct_id>NCT04620889</nct_id>
  </id_info>
  <brief_title>LeMaitre LifeSpan® ePTFE Vascular Graft Retrospective Registry</brief_title>
  <official_title>A Retrospective Patient Registry on the Long-Term Safety and Performance of the LifeSpan® ePTFE Vascular Graft Used in Open Vascular Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LeMaitre Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LeMaitre Vascular</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a post-market, single-arm, retrospective registry. The investigator or its&#xD;
      representative will identify eligible patients through a medical record search. Data will be&#xD;
      captured retrospectively. Subjects will have been treated with the investigational device in&#xD;
      the past and according to standard of care. Subjects will not be involved in any registry&#xD;
      related procedures.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 27, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of vessels patent without requiring intervention to remain open</measure>
    <time_frame>3 years</time_frame>
    <description>Percentage of patients exempt from thrombosis/ occlusion and/or restenosis of the target lesion during follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of vessels patent without requiring intervention to remain open</measure>
    <time_frame>2 years</time_frame>
    <description>Percentage of patients exempt from thrombosis/ occlusion and/or restenosis of the target lesion during follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure type</measure>
    <time_frame>Day of procedure</time_frame>
    <description>Type of procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-operative technical success</measure>
    <time_frame>Day of procedure</time_frame>
    <description>Percentage of patients with proper functioning of the device in the opinion of the investigator at time of surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of vessels patent without requiring intervention to remain open at 1 and 5 year primary patency</measure>
    <time_frame>1 year and 5 year</time_frame>
    <description>Percentage of patients exempt from thrombosis/ occlusion and/or restenosis of the target lesion during follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of vessels patent with intervention to remain open at 1 and 5 year</measure>
    <time_frame>1 year and 5 year</time_frame>
    <description>Percentage of patients exempt from thrombosis/ occlusion and/or restenosis of the target lesion during follow-up after interventions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of vessels patent with intervention to remain open at 1 and 5 year for AV Access</measure>
    <time_frame>2 year</time_frame>
    <description>Percentage of patients exempt from thrombosis/ occlusion and/or restenosis of the target lesion during follow-up after interventions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of vessels patent with intervention to remain open at 1 and 5 year for PVP Group</measure>
    <time_frame>3 year</time_frame>
    <description>Percentage of patients exempt from thrombosis/ occlusion and/or restenosis of the target lesion during follow-up after interventions</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">177</enrollment>
  <condition>Diseased or Occluded Blood Vessels</condition>
  <condition>Arteriovenous Shunting for Blood Access</condition>
  <arm_group>
    <arm_group_label>PVP</arm_group_label>
    <description>Bypass or reconstruction of diseased or occluded blood vessels</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AV Access</arm_group_label>
    <description>Arteriovenous shunting for blood access.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AV Access</intervention_name>
    <description>Arteriovenous shunting for blood access.</description>
    <arm_group_label>AV Access</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PVP</intervention_name>
    <description>Bypass or reconstruction of diseased or occluded blood vessels</description>
    <arm_group_label>PVP</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This is a retrospective registry. The included population is therefore directly&#xD;
        representative of the population in a real-world environment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has undergone surgical treatment with the LifeSpan.&#xD;
&#xD;
          -  Surgical treatment was for bypass or reconstruction of diseased or occluded blood&#xD;
             vessels (PVP group) or arteriovenous shunting for blood access (AV group).&#xD;
&#xD;
          -  For PVP group: Subject's surgical treatment was at minimum 3 years ago, and maximum 10&#xD;
             years ago, at time of enrollment.&#xD;
&#xD;
          -  For AV group: Subject's surgical treatment was at minimum 2 years ago, and maximum 10&#xD;
             years ago, at time of enrollment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Brian K Orrick</last_name>
    <phone>781-425-1685</phone>
    <email>jasmin.staewen@klinikum-nf.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinikum Nordfriesland GmbH</name>
      <address>
        <city>Husum</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jasmin Staewen</last_name>
      <email>jasmin.staewen@klinikum-nf.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2020</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This is a fully anonymized registry. No IPD will be collected or shared.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

